Is deze al geplaatst?:
======================
Pharming Group (PHGUF) Rating Increased to Hold at Zacks Investment Research
October 25th, 2018 - By Gary James
Pharming Group logoPharming Group (OTCMKTS:PHGUF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, October 16th.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Get Pharming Group alerts:
Shares of Pharming Group stock opened at $1.10 on Tuesday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.28 and a current ratio of 1.64. Pharming Group has a 52-week low of $0.84 and a 52-week high of $1.96. The firm has a market capitalization of $636.92 million, a price-to-earnings ratio of -6.11 and a beta of 2.94.
Pharming Group (OTCMKTS:PHGUF) last posted its earnings results on Thursday, July 26th. The biotechnology company reported $0.01 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. Pharming Group had a negative net margin of 36.30% and a negative return on equity of 176.01%. The business had revenue of $35.77 million for the quarter, compared to analyst estimates of $38.86 million. Analysts expect that Pharming Group will post 0.04 EPS for the current fiscal year.
About Pharming Group
Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein.
Read More: Understanding each part of a balance sheet
Get a free copy of the Zacks research report on Pharming Group (PHGUF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.